At Asembia AXS26, one message surfaced repeatedly across conversations with manufacturers, specialty pharmacies, hubs, and patient support leaders: healthcare fragmentation is becoming impossible to ignore.
Disconnected systems, siloed vendors, fragmented patient journeys, and outdated support models are creating increasing operational friction across specialty care. In many cases, adherence visibility still stops at the mailbox, while patient engagement remains disconnected from the broader ecosystem influencing outcomes.
RxPx APAC General Manager Monisha Nair and Chief Strategy Officer Tessa Angle observed a noticeable shift in the industry dialogue throughout the summit. The mood felt less focused on showcasing standalone solutions and more centered on acknowledging what is no longer working – particularly in specialty and rare disease care, where coordinated, longitudinal support is critical.
As Monisha Nair noted, “The number one pain point at Asembia wasn’t AI, it was fragmentation. Brands have the tools, the data and the services, but nothing is connected across the full patient journey. AI is being bolted on rather than embedded, hub models are too resource-heavy without the intelligence to match, and the demand for a single enterprise platform that brings it all together with humans in the loop has never been louder.”
That growing tension between technology advancement and disconnected execution surfaced repeatedly throughout the conference.
“The shift I noticed wasn’t just in what people were talking about…it was in what they were willing to admit,” said Tessa Angle, Chief Strategy Officer at RxPx. “The industry has spent years investing in tools, data, and AI capabilities, but the conversations at AXS26 felt more honest about the gap between having those capabilities and actually using them to support patients better.”
Angle also noted that one idea consistently emerged as non-negotiable: “Humans in the loop. Not as a safety net for when technology falls short, but as an intentional part of how the best support models are being designed. In specialty and rare disease, that distinction matters enormously.”
Several themes consistently emerged from those discussions.
Fragmentation Is Becoming the Defining Industry Pain Point
Brands today operate across highly fragmented ecosystems: disconnected CRM platforms, contact centers, pharmacy systems, lab data, PV feeds, and patient support programs that often function independently rather than cohesively.
The result is operational drag, inconsistent patient experiences, and support models that struggle to evolve beyond traditional hub structures. Many organizations acknowledged that existing PSP approaches are increasingly being recycled across brands without addressing the underlying coordination challenges patients face throughout their treatment journey.
AI Is Evolving From Automation to Orchestration
One of the more nuanced conversations at AXS26 centered around AI’s evolving role in patient engagement.
The value of AI is no longer simply about automation. The conversation is shifting toward how intelligent technology can enable more personalized, proactive engagement at scale – while supporting better coordination across increasingly complex patient journeys.
Behavioral sciences adds a critical layer to this evolution. Understanding why patients disengage, what drives sustained adherence, and how to design interventions that influence meaningful behavior change is what separates sophisticated support models from programs that simply automate the status quo.
What stood out most throughout the summit was a growing recognition that AI alone is not the answer. The strongest positioning consistently emphasized AI as an enabler of better care orchestration, rather than a replacement for the human relationships that remain essential in specialty care.
Human Connection Remains Essential
Despite rapid advances in digital engagement, one theme remained clear: specialty and rare disease patients still require empathy, trust, coaching, and community.
The concept of the “human in the loop” resonated strongly throughout AXS26 discussions, reinforcing that technology works best when paired with meaningful human support rather than positioned as a replacement for it.
The Future Belongs to Ecosystem Integrators
Perhaps the strongest strategic shift emerging from the conference was the growing emphasis on interoperability and connected ecosystems.
The most valuable platforms are no longer the ones attempting to replace existing stakeholders. They are the ones elevating and connecting them.
Across conversations, there was increasing focus on integrating lab monitoring, pharmacy systems, PV data, wearable technologies, care teams, and real-world patient insights into more coordinated engagement models. The industry is moving toward platforms that can leverage existing resources and external data sources to create more dynamic, actionable patient experiences.
This “elevate, don’t replace” mindset closely reflects how RxPx approaches specialty patient engagement: combining intelligent technology, behavioral science, and human support within a connected ecosystem model designed to improve coordination, personalization, and longitudinal patient outcomes.
AXS26 reinforced that the future of specialty care will belong to organizations capable of balancing AI-enabled personalization with human-centered engagement – while reducing the fragmentation that continues to challenge patients, providers, and care teams across the healthcare journey.
